Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with HER2+ stage IV breast cancer that have been maximally treated and not in a complete remission~* Patients must have measurable disease per imaging studies performed within 60 days of enrollment as described below:~  * Extra skeletal disease that can be measured with conventional or spiral computed tomography (CT) techniques~ * Skeletal or bone-only disease that is measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) or magnetic resonance imaging (MRI)~* Patients can be receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy~* HER2 overexpression in the primary tumor or metastasis by immunohistochemistry (IHC) of 3+, or documented gene amplification by fluorescent in situ hybridization (FISH) analysis~* Patients must be human leukocyte antigen (HLA)-A2 positive~* Eastern Cooperative Oncology Group (ECOG)/Zubrod scale of =\< 1~* Patients must be off immunosuppressive treatments (i.e., chemotherapy or systemic steroids) 3 weeks prior to first vaccine~* Patients on trastuzumab must have a baseline left ventricular ejection fraction (LVEF) measured by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) \>= the lower limit of normal for the facility within 3 months of enrollment to study~* Subjects of reproductive ability must agree to use contraceptives during the entire study period~Exclusion Criteria:~* White blood cell (WBC) \< 3000/mm\^3~* Hemoglobin (Hgb) \< 10 mg/dl~* Platelets \< 100,000/mm\^3~* Serum creatinine \> 2.0 mg/dl~* Serum bilirubin \> 1.5 x upper limit of normal~* Any contraindication to receiving sargramostim (GM-CSF) based vaccine products~* Concurrent enrollment in other treatment studies~* New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina~* Pregnant or breast-feeding women~* History of disorders associated with immunosuppression such as human immunodeficiency virus (HIV)~* Active brain metastasis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (HER-2/neu peptide vaccine) (Type: EXPERIMENTAL): Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).